Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Trzonkowski

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Nature Communications|February 15, 2022
Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activityKarolina Piekarska, Zuzanna Urban-Wójciuk, Małgorzta Kurkowiak, et al.
Immunity & Ageing : I & A|November 3, 2022
Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donorsMichał Cezary Czarnogórski, Justyna Sakowska, Mateusz Maziewski, et al.
Frontiers in Immunology|November 29, 2023
High maternal-fetal HLA eplet compatibility is associated with severe manifestation of preeclampsiaKatarzyna Stefańska, Małgorzata Kurkowiak, Karolina Piekarska, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 5, 2021
Administration of CD4<sup>+</sup>CD25<sup>high</sup>CD127<sup>-</sup>FoxP3<sup>+</sup> Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 StudyKamil Chwojnicki, Dorota Iwaszkiewicz-Grześ, Anna Jankowska, et al.
Diabetes, Obesity & Metabolism|April 20, 2022
Combined therapy with CD4<sup>+</sup> CD25highCD127<sup>-</sup> T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trialMaciej Zieliński, Magdalena Żalińska, Dorota Iwaszkiewicz-Grześ, et al.
Frontiers in Immunology|August 1, 2022
KIR- Ligand Interactions in Hypertensive Disorders in PregnancyKatarzyna Stefańska, Martyna Tomaszewicz, Joanna Dębska-Zielkowska, et al.
Diabetes, Obesity & Metabolism|November 26, 2025
Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adultMarta Bandura, Magdalena Piotrowska-Mieczkowska, Matylda Hennig, et al.
Journal of Translational Medicine|December 2, 2016
Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetesNatalia Marek-Trzonkowska, Małgorzata Myśliwiec, Dorota Iwaszkiewicz-Grześ, et al.
BMJ Open Diabetes Research & Care|February 27, 2020
Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapyMateusz Gliwiński, Dorota Iwaszkiewicz-Grześ, Anna Wołoszyn-Durkiewicz, et al.
International Immunopharmacology|March 30, 2024
PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity ameliorationMaciej Zieliński, Justyna Sakowska, Dorota Iwaszkiewicz-Grześ, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Nature Communications|February 15, 2022
Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activityKarolina Piekarska, Zuzanna Urban-Wójciuk, Małgorzta Kurkowiak, et al.
Immunity & Ageing : I & A|November 3, 2022
Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donorsMichał Cezary Czarnogórski, Justyna Sakowska, Mateusz Maziewski, et al.
Frontiers in Immunology|November 29, 2023
High maternal-fetal HLA eplet compatibility is associated with severe manifestation of preeclampsiaKatarzyna Stefańska, Małgorzata Kurkowiak, Karolina Piekarska, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 5, 2021
Administration of CD4<sup>+</sup>CD25<sup>high</sup>CD127<sup>-</sup>FoxP3<sup>+</sup> Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 StudyKamil Chwojnicki, Dorota Iwaszkiewicz-Grześ, Anna Jankowska, et al.
Diabetes, Obesity & Metabolism|April 20, 2022
Combined therapy with CD4<sup>+</sup> CD25highCD127<sup>-</sup> T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trialMaciej Zieliński, Magdalena Żalińska, Dorota Iwaszkiewicz-Grześ, et al.
Frontiers in Immunology|August 1, 2022
KIR- Ligand Interactions in Hypertensive Disorders in PregnancyKatarzyna Stefańska, Martyna Tomaszewicz, Joanna Dębska-Zielkowska, et al.
Diabetes, Obesity & Metabolism|November 26, 2025
Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adultMarta Bandura, Magdalena Piotrowska-Mieczkowska, Matylda Hennig, et al.
Journal of Translational Medicine|December 2, 2016
Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetesNatalia Marek-Trzonkowska, Małgorzata Myśliwiec, Dorota Iwaszkiewicz-Grześ, et al.
BMJ Open Diabetes Research & Care|February 27, 2020
Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapyMateusz Gliwiński, Dorota Iwaszkiewicz-Grześ, Anna Wołoszyn-Durkiewicz, et al.
International Immunopharmacology|March 30, 2024
PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity ameliorationMaciej Zieliński, Justyna Sakowska, Dorota Iwaszkiewicz-Grześ, et al.
Pageof 17